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Abstract 
The efficacy and immune-modulation of mesenchymal stem cells is well documented. The issue of obtaining 
mesenchymal stem cells without patient risk, extensive intra-operative procedure, cell manipulation or exposure 
of cells to harmful reagents remains an issue. This study was designed to test the viability, composition and 
osteogenic potential of cells derived from cadaveric bone marrow by a new process. Vertebral bone from 
cadavers was collected within 24 hours of death, processed by a new procedure of tumbling and collection, and 
evaluated for viability, marker expression, cell composition, and inflammatory properties at various stages of the 
isolation process and following cryopreservation. Viability was excellent in all fractions and at all stages of the 
study. Cell staining and microscopic observation showed increased erythrocyte content in the first tumble of 
bone for marrow extraction, as well as gross observation of debris.  
------------------------------------------------------------------------ 
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Cryopreservation favored the preservation of CD45-/CD105+ and GlycoA-/STRO-1+ mesenchymal stem cells 
at the expense of platelets, red blood cells, white blood cells and neutrophils. The resulting cell solution contains 
a percentage of mesenchymal stem cells far above that required for immune modulation. A mixed lymphocyte 
reaction assay showed no inflammatory response to this cell composition. The cells produced and preserved in 
this manner are viable, should elicit no immune response, suppress recipient immune responses and 
osteogenically differentiate.  
Keywords: MSC; cadaveric; cryopreservation; immune modulation; fracture repair. 
1. Introduction  
Due to their inherent osteogenic capacity and immunomodulatory properties, multipotent mesenchymal stem 
cells (MSCs) are strongly desired for fracture repair. It has been known since 2002 that MSCs suppress T-cell 
proliferation in mixed lymphocyte cultures [1]. With the inhibition of T-cell allo-responses widely documented 
[2, 3] an abundance of research has subsequently investigated the use of MSCs with skin [4, 5], cardiac [6], liver 
transplants [7], islet transplant [8, 9] and for the amelioration of Graft Versus Host Disease (GVHD) [10, 11, 12] 
and consistently demonstrated a lack of immune response or graft rejection. This has established bone marrow 
(BM) MSCs as a safe and advantageous component for allograft, with doses as low as 10,000 MSCs shown to 
be effective [2]. 
The metrics of dosage, concentration, carrier and effective tissue response to cell compositions all support 
regenerative applications, but the problem remains that the bone marrow contains a large variety of cell types. If 
one desires to separate MSCs from this mix of cells, centrifugal separation can segregate cells of specific 
density ranges, but cannot isolate specific cell types within that density range. Several methods of specific 
identification and separation have been developed with magnetically coupled antibodies, however the use of 
antibody-based cell isolation has not been approved for use beyond research applications with the exception of 
CD34 (cleared by the FDA, January 2014) for treatment of Acute Myeloid Leukemia. In the effort to achieve a 
pure cell determinant, or cluster of determination (CD), many of the cell types discarded during specific 
isolation are supportive of the regeneration process and MSC proliferation. The frustration of wasted 
regenerative potential in conjunction with the desire to retain the immunomodulatory characteristics of MSCs 
lead us to believe that the isolation of specific cell types may be unnecessary, impractical and perhaps even 
undesirable. We propose that the presence of supportive cell populations in combination with MSCs yields an 
attractive allograft that can not only be safely transplanted, but moreover supports effective regenerative 
potential. Further, this viable cellular allograft can also be attained without significant cell manipulation, without 
exposure of cells to enzymes that cleave cell attachment (eg. collagenase) or toxic, and devoid of damaging 
cryopreservants (eg. DMSO) or cryopreservants that contain potentially unsafe serums. 
CD105 (endoglin) and STRO-1 are well known markers of mesenchymal stem cells [13, 14, 15, 16]. 
Additionally, STRO-1+ cells are 100 times more osteogenic than STRO-1- cells [17]. Therefore, we utilized 
CD105 and STRO-1 as markers for MSCs with predisposition to osteogenic capacity. A process was developed 
to evaluate the safety and osteogenic efficacy of a cellular suspension obtained by tumbling cadaveric bone 
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marrow, centrifugal separation followed with ficoll, and preservation in poly-l-lysine-based polyampholyte 
cryopreservant for potential use as allograft material. The key indicators sought were the percentage of MSCs in 
cell solution, the imposition of immunomodulation of both donor and recipient, the ability to osteogenically 
differentiate and the absence of significant deleterious manipulation of the cells.  
2. Materials and methods 
2.1. Isolation of cellular suspension 
Donor spines were collected and surrounding soft tissue and fascia was removed. Individual vertebral bodies, 
primarily cancellous bone in composition, were dissected free of the intervertebral disks and further trimmed 
into small pieces. The pieces were further ground to small chunks of 4-10 mm and placed in processing media 
(low glucose DMEM with 2.5% HSA, 10 U/ml Heparin, 0.08 mg/ml Gentamicin and 0.0025 mg/ml DNAse). 
The resulting slurry was tumbled 4 times. The solution was collected after each tumble and replaced by more 
processing media. The collected solution was passed through 500 μm, followed by 180 μm sieves. 
2.2. Gross and microscopic evaluation 
2.2.1. Cell suspensions 
Cells from each tumble (1-4), were ficoll separated and viewed with a Nikon DIAPHOT microscope at 10x 
magnification with SpotAdvanced Version 4.1 software. 
2.2.2. Alkaline phosphatase and mineralization 
The alkaline phosphatase reaction was photographed using a Nikon DIAPHOT microscope at 4x magnification 
with SpotAdvanced Version 4.1 software. Reaction products from six-well plates of alkaline phosphatase 
secretion and mineralization were recorded with a Samsung Galaxy S5 camera. 
2.3. Viability 
Pre-and Post-Ficoll samples were stained for viability with propidium iodide. Viability was measured as cells 
negative for propidium iodide with a Moxi Flow™ cell counter (Orflo technologies, United States). The Post-
thaw samples were counted and assessed for viability by trypan blue staining and counting with a 
hemocytometer. 
2.4. Flow cytometry 
Cells were stained for flow cytometry in FACS buffer (DPBS, 5% BSA, 0.01% sodium azide) with either 
CD15-AF488, CD45-APC, HLADR-FITC, CD3-APC (BioLegend, U.S.A.), CD37-PE, HLA class1-APC, 
SSEA4-FITC, GlycoA-PE (R&D Systems, U.S.A.), GlycoA-PE + STRO-1-APC (Novus Biologicals, U.S.A.), 
CD45-APC + CD105-FITC (R&D Systems) or isotype controls for each fluorophore for 30 minutes at 4-80C in 
the dark. The cells were then washed twice with FACS buffer and re-suspended in 4% paraformaldehyde. Flow 
cytometry data was collected on a BD LSR II flow cytometer (BD Biosciences, U.S.A.). All positive/negative 
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signals were obtained by comparison with isotype control. 
2.5. Complete blood counts 
Samples were sent to Sylvester Cancer Center for Complete Blood Count by the Diagnostic Molecular 
Pathology and Flow Cytometry Laboratory. 
2.6. Efficacy assay 
Cells were seeded in fibronectin-coated 6-well plates and allowed to attach at 370C overnight. The media was 
changed to osteogenic differentiation media (alpha-MEM, 10% FBS, 1% P/S, 100uM Ascorbic Acid, 10 mM B-
glycerophosphate and 10 nM dexamethasone) and plates were incubated at 370C, 5% CO2 for up to 21 days. In 
indicated assays, the cells were allowed to grow to near confluence before transition to differentiation media. 
2.6.1. Alkaline phosphatase activity 
The media was aspirated and cells were washed twice with DPBS. Cells were fixed in 2% paraformaldehyde for 
30 minutes. The cells were again washed two times with DPBS then covered with alkaline phosphatase substrate 
solution (1.85 mM napthol, 1% n-n'dimethylformamide, 1.68 mM Fast Blue B Salt, 3.5 mM magnesium 
chloride in 30 ml 100 mM Tris-HCl pH 9.6, final solution adjusted to pH 9.0) then incubated for 30 minutes at 
370C. The alkaline phosphatase substrate solution was aspirated and cells were washed twice in DPBS and 
allowed to dry for photography. 
2.6.2. Mineralization 
The media was aspirated and cells were washed two times with DPBS. Cells were fixed in 2% 
paraformaldehyde for one hour. The cells were again washed two times with DPBS then covered with Alizarin 
Red solution (40 mM Alizarin Red-S pH 4.2) and incubated for 20 minutes at room temperature. The alizarin 
red solution was aspirated and cells were washed twice with DI water and allowed to dry for photography. 
2.7. Cryopreservation and thaw 
2.7.1. Cryopreservation 
Cells were re-suspended in a non-DMSO, polyampholyte cryoprotectant to a concentration of 1.1 x 106 cells/ml. 
One milliliter aliquots were transferred to cryovials and allowed to equilibrate for 30-45 minutes. The vials were 
then frozen at 100C/minute and stored at -800C. 
2.7.2. Thaw 
Cells were quickly thawed in a 370C water bath and transferred into 3 ml of physiological saline. Cell counts, 
viability and flow cytometry samples were taken from this solution. 
2.8. MLR reactions 
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A mixed lymphocyte reaction was contracted to an independent laboratory who used a Roche BrdU ELISA 
proliferation assay. A total of seven samples were sent. The immune response was measured and converted into 
stimulation indexes (SI) with an n of 1-3 for each sample. 
2.9. Statistical analysis 
Data are reported as mean ± s.d. All analyses were performed using Microsoft Excel data analysis for two-tailed 
Student’s T-test. Differences between populations with significance p<0.05 were considered statistically 
significant. 
2.10. Use of human subjects 
Whole bone marrow was obtained from the vertebral bodies of cadaveric male donors (age range; 22- to 52-
years old) following guidelines for informed consent set by the University of Miami, School of Medicine, 
Committee on the Use of Human Subjects in Research. Vertebrae were removed from normal donors within 24 
hours of death and serology was performed to assure safe source and reduced risk of disease transmission. 
3. Results 
3.1. Phenotypic composition of tumbles used for cell collection 
To better understand a composition defining cells desired vs. cells that might be potentially immunogenic, cells  
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Figure 1: Four tumbles of vertebral bone marrow pieces result in different debris and erythrocyte content but 
maintain viability. (a) Representative ficoll separations of each tumble for a single donor. The first tumble 
clearly shows a large RBC pellet as well as a red upper fraction. The MNC ring is not apparent. The other 
tumbles have sequentially smaller RBC pellets, clearer upper fractions and more apparent MNC rings. (b) 
Microscopic hemocytometer images of the collected MNC layer of each tumble from a single donor. The first 
tumble shows more debris and cells that are not clearly round. The remaining tumbles have significantly 
reduced debris and primarily round healthy cells. (c) Flow analysis of GlycoA positive cells before and after 
ficoll separation for each tumble. The first tumble has the highest percentage of GlycoA positive cells. All 
tumbles had reduced percentages of GlycoA+ cells following ficoll separation. (d) The viability of cells by 
propidium iodide reveals no difference between tumbles before or after ficoll separation. N=3, *P<0.05. 
In each of several washes and tumbles were evaluated separately during cell collection. Gross composition, 
viability and phenotypic composition were analyzed. The suspension from each tumble was separated by density 
gradient centrifugation. Gross observation of the centrifugally separated samples revealed differences in the 
content of all fractions (Figure 1a). Most obvious was the extent of hemolyzed material in the upper fraction of 
Tumble 1 as well as the large red pellet on the bottom, red blood cells (RBCs). An apparent white mononuclear 
cell ring at the Ficoll interface was minimal, if not absent. These properties diminished with each subsequent 
tumble. Microscopic evaluation of the mononuclear cell fraction ring revealed more debris and red blood cells in 
the first tumble, with less debris and more mononuclear cells occurring in each subsequent tumble (Figure 1b). 
Subsequent cell staining for GlycoA (differentiated erythrocytes) emphasized the high RBC content of Tumble 
1, as well as the significant reduction of such cells following ficoll separation (Figure 1c). Propidium iodide 
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staining of each tumble revealed no significant difference in viability between any of the tumbles or between 
pre- and post-ficoll separations (Figure 1d). The mononuclear cells from each tumble were stained for typical 
hematopoietic, granulocyte and immune cell markers, as well as the primitive stem cell marker SSEA4 and 
mesenchymal stem cell marker CD105. Additionally, the samples were sent to the Sylvester Cancer Center for 
complete blood differential count (CBC). It is noteworthy that the first tumble (pre-ficoll) was too coagulated 
for CBC in all cases. Separation of the mononuclear cell fraction from the remainder of the solution made the 
CBC (post-ficoll) possible. For this reason, all subsequent analysis were only performed on post-ficoll 
separation samples. The CBC revealed no statistically significant difference between the tumbles in any of the 
cell populations measured (Figure 2a), although the lymphocytes appear to be drastically reduced after the first 
tumble. Cell staining (Figure 2b) revealed no significant difference in CD15 (granulocyte marker) expression 
between the tumbles, providing verification of the CBC data which showed no significant difference in 
neutrophils and basophils. In addition, the cell staining showed a reduction of Human leukocyte antigen-D 
related (HLADR) with each tumble but, like the CBC, the results are not statistically significant (Figure 2b). 
There was no difference in the primitive MSC marker, SSEA4, or MSC marker CD105, between the tumbles 
(Figure 2c). Donor variability, inherent in this process, played a large part as seen by the error bars in all graphs 
in Figure 2. Therefore, reducing the undesirable cells and debris from Tumble 1 seems to provide increased 
safety without affecting any prospective efficacy. For this reason, we eliminated tumble 1 from all subsequent 
analyses and combined the solutions from tumbles 2-4 for ficoll separation.  
 
a 
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Figure 2: There is no difference in phenotypic composition between each tumble following ficoll separation. (a) 
Complete blood count reveals no difference in indicated cell types between tumbles, measured as percent of 
WBC’s. (b) Flow cytometry shows no difference in indicated hematopoietic markers between tumbles, 
measured as a percent of all cells. (c) There is no difference between tumbles in the percent of mesenchymal 
stem cells that are SSEA4 positive or CD105 positive. N=3, *p<0.05. 
3.2. The isolated cells are osteogenic and mineralize 
In order to ensure that the cells isolated were osteogenic, cells were placed in osteogenic media and their 
production of alkaline phosphatase and level of mineralization at various time points were evaluated.  Figure 3a 
shows the production of alkaline phosphatase by the cell suspension. The cells were seeded at 1.1 x 106 
cells/well and not allowed to expand. They were osteogenically differentiated 24 hours after the time of plating. 
Colonies formed with the typical swirling pattern of differentiating osteoblasts. The low magnification and 
microscopic images in Figure 3b show the edges of colonies. Both images illustrate the alkaline phosphatase 
activity highest at the centers where the cells are more confluent and diminishing outward as the cells are 
proliferating and differentiating outward. In the following experiment, cells were seeded at the same density and 
allowed to expand to near confluency, then differentiated with exposure to osteogenic media. There was obvious 
alkaline phosphatase activity peaking at day 14 and waning at day 21(Figure 3c), as expected when cells transfer 
from differentiation to mineralization [18, 19]. Alizarin Red staining in Figure 3d shows the samples miner 
alizing at day 21. This correlates with the decrease in alkaline phosphatase, as it is known that cells will first 
secrete alkaline phosphatase, then reduce that secretion in favor of mineralization. These data confirm that the 
cell solution is osteogenic, and will mineralize, illustrating the ability of the cell solution to effectively produce 
bone. 
3.3. The cryopreserved cell suspension is safe for direct implantation 
The cells were cryopreserved in a poly-l-lysine based preservation media with no dilution or additions. After 30 
days of cryopreservation vials from three different donors were sent out for Mixed Lymphocyte Reaction 
(MLR) testing to evaluate the safety of direct application of the cell solution. A histogram of the resulting 
Stimulation Indexes (SI) for each test shows that no reaction occurred with any of our cell solutions (Figure 4). 
Based on these results, the cryopreserved cell solution should elicit no immune response. 
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Figure 3: Cells collected by this new method form colonies and are osteogenic. (a) Representative photograph 
of post ficoll cells grown in osteogenic media for 30 days. No prior expansion was allowed.  Alkaline 
phosphatase staining shows many colonies at varying densities positive for alkaline phosphatase secretion. (b) 
Representative photograph of post ficoll cells from a different donor grown in osteogenic media for 14 days. No 
prior expansion was allowed.  Low magnification and 4X magnification of alkaline phosphatase staining shows 
typical swirling pattern within colonies which are positive for alkaline phosphatase secretion. (c) Representative 
photographs of alkaline phosphatase staining of post ficoll cells from a different donor that were allowed to 
expand to near confluence, then differentiated in osteogenic media for up to 21 days. (d) Representative 
photographs of Alizarin Red staining of post ficoll cells from the same donor as in (c) that were allowed to 
expand to near confluence, then differentiated in osteogenic media for up to 21 days. 
 
Figure 4: The cell solution does not elicit an immune response. Seven separate frozen donor samples were sent 
out for mixed lymphocyte reaction (MLR) testing. The MLR performed by Xeno Diagnostics shows no 
difference in the stimulation index between stimulated test cells and unstimulated control cells. Positive controls 
(PBMCs) clearly showed significant stimulation. N=3 for six samples, n=1 for the seventh sample. mitC= 
mytomycin C treated. PHA= phytohemagglutinin treated. Allo= allogenic reaction. 
3.4. The cells have reduced blood cells and increased MSC content upon thaw 
The final analysis of this study was to ascertain the viability and composition of the cell suspension after 
cryopreservation. We sought to determine these parameters after 90 days and 6 months of cryopreservation. 
Viability was not significantly different between cells before freezing (pre-freeze) and those thawed at 90 days 
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or thawed at 6 months (Figure 5a). The Complete Differential Blood Count (CBC) in Figure 5b shows that 
although ficoll separation significantly reduced the percentage of platelets and red blood cells, cryopreservation 
for 90 days further reduced the platelets, RBCs and WBCs. The CBC (Figure 5c) also shows that ficoll 
separation alone was responsible for significant reduction in lymphocytes and monocytes. In such depletion, the 
relative number of neutrophils, large unstained cells (LUC) and basophils appeared to increase in proportion to 
the total number of cells. Following 90 days of cryopreservation, the thawed cells showed significant reduction 
in neutrophils and an increase in monocytes, eosinophils and basophils compared to pre-freeze samples. Cell 
staining for flow cytometry showed that after 6 months of cryopreservation, there is no significant change in 
CD15 or CD3 compared to pre-freeze (Figure 5d). The B-cell marker, CD37 was completely (and significantly) 
lost. The hematopoietic marker, CD45, was reduced almost to significance (p=0.08) and cells expressing HLA 
class 1 were significantly reduced. Surprisingly, HLADR was significantly increased after 6 months of 
cryopreservation (Figure 5d). As expected, the percentage of cells expressing GlycoA (differentiated 
erythrocytes) was significantly reduced after 6 months of cryopreservation (Figure 5e). Interestingly, the 
percentage of cells negative for hematopoietic marker CD45 and expressing mesenchymal stem cell marker 
CD105 increased significantly following 6 months of cryopreservation compared to pre-freeze (Figure 5f). 
Similarly, the percentage of cells that are negative for the erythrocyte marker GlycoA and positive for the 
osteogenic MSC marker STRO-1 increased significantly at 6 months thaw compared to pre-freeze (Figure 5f). 
The observation supported by this data suggests that freezing in poly-l-lysine-based cryopreservant 
preferentially results in lysis of erythrocytes, lymphocytes and neutrophils, and in consequence augments the 
percentage of viable MSC’s. 
4. Conclusion 
The production of safe, effective allograft material is challenging. Current regulations preclude the use of 
antibody-based isolation and separation of specific cell types, and furthermore, highly selective isolation 
techniques would remove desirable supportive cell populations. In the reflection of bone marrow offering a 
multitude of potentials in a mosaic of identities, an ideal allograft should contain supportive cell populations yet 
maintain a high enough percentage of MSCs to abrogate any inflammatory or immune effects to both allograft 
and recipient. We have isolated a cell solution that is both safe, due to the high percentage of MSCs, and 
effective due to the presence of several supportive cell populations in coordination with the MSCs. 
The elimination of debris, erythrocytes, and considerable amounts of leukocytes and HLADR+ cells by removal 
of cells from the first tumble establishes a more favorable baseline group of cells for ficoll separation. Observed 
debris may be due to necrosis, dying cells or platelets, all of which are not desired in this allograft product. This 
is illustrated by the extensive clotting of the pre-ficoll cells from tumble 1, barring CBC analysis. Fortunately, 
supportive cells remain in the remaining three fractions, allowing retention for ficoll separation. 
Tumbles 2 through 4 in our processing media were combined and separated by density gradient centrifugation 
with ficoll. The recovered MNC layer secretes alkaline phosphatase at 14 days and begins mineralization at 21 
days. This clearly demonstrates the osteogenic capacity of these cells upon introduction to osteogenic factors. 
Introduction of this cell mixture to an environment rich in bone forming niche cells (e.g. osteoblasts, osteoclasts, 
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matrix, etc.) such as demineralized bone and the in vivo niche would further promote the efficacy of the MSC 
component, increasing the efficacy of the supporting cells by feedback. 
 
Figure 5: The phenotypic profile of the cell solution following cryopreservation. (a) The viability as measured 
by trypan blue staining shows high viability following cryopreservation with no difference between pre-freeze 
(n=42), 90 days frozen (n=9) and 6 months frozen (n=8). (b) Complete blood count shows a significant decrease 
in the number of platelets, red blood cells (RBCs) and white blood cells (WBC) following ficoll separation, 
before freeze (n=17) and again after 90 days of cryopreservation (n=6). (c) Complete blood count shows 
significant changes in some cell types within the WBC count following ficoll separation, before freeze (n=17) 
and after 90 days of cryopreservation (n=6). (d) Flow cytometry analysis reveals a significant decrease in the 
percentage of CD37 positive B-cells and HLA class I cells and a significant increase in the percentage of 
HLADR positive cells after 6 months in cryopreservation (n=8) compared to pre-freeze (n=38). (e) GlycoA 
staining of cells before freeze (n=35) and after 6 months of cryopreservation (n=8) show the significant decrease 
in the percentage of erythrocytes in the cell solution. (f) Flow cytometry analysis of MSC markers show that 
following 6 months of cryopreservation (n=8) the percentage of CD45-/CD105+ and GlycoA-/STRO-1+ cells 
are significantly increased compared to pre-freeze percentages (n=37). *p<0.05, **p<0.01, ***p<0.001. 
The choice of a poly-l-lysine based cryopreservant proved to be an important component as it appears to 
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preferentially preserve desirable cells. The pH of the poly-l-lysine used may have played a role in its preferential 
preservation of MSC populations [20]. The poly-l-lysine cryoprotectant is safe for direct in vivo injection as 
evidenced by both in vitro studies [21, 22] and mixed lymphocyte reaction testing directly applied to the 
individual lots of donor allograft material. All thawed populations retained high viability when re-suspended in 
physiological saline with no centrifugation or washing of cells. As expected, RBCs and platelets were further 
eliminated during freezing, most likely due to lysis [23]. This is advantageous as platelet rich plasma (the 
product of factors released from lysed platelets during freeze) is currently being utilized as a healing therapy 
[24, 25] although The American Academy of Orthopaedic Surgeons concluded in 2011 that its effectiveness is 
still unproven. The increase in HLADR positive cells was evaluated to ensure safety. Cells that express HLADR 
on their surface include macrophages, B-cells and dendritic cells [26, 27]. The percentage of cells expressing 
CD37 (B-cells) was near zero, macrophages (monocytes) were less than 17% of the WBC’s, which amounts to 
4.8% of total cells. Since the isolate was recovered from the bone marrow, this leaves the balance as immature 
dendritic cells with low T-cell activation potential. Moreover, MSCs have been shown to suppress immune 
reactions by modulating dendritic cells [28]. 
The elimination of B-cells and reduction of T-cells to within one s.d. of zero is ideal. Since these cells were 
frozen at 1.1 x 106 cells per vial, 50% CD45-CD105+ cells amount to 550,000 MSCs in a single vial. This cell 
population has been repeatedly shown to be MSCs [13, 29]. It has been reported that MSCs suppress immune 
reactions [30, 31, 32] avoid allogeneic recognition, interfere with dendritic cell and T-cell function, and generate 
a local immunosuppressive microenvironment by secreting cytokines [33]. And perhaps most importantly, 
10,000 MSCs (10%) sufficiently supports and conveys an immunosuppressive effect to donor cells and recipient 
cells following transplant [34]. It has also been shown that the immunomodulatory function of human MSCs is 
further enhanced when the cells are exposed to an inflammatory environment [35]. Since our cells exceed that 
requirement by 5 times, the cell solution is shown to be safe from immune reaction from both donor and 
recipient. These data illustrate the safety of the cell solution obtained and preserved in this manner. 
The non-erythrocyte (GlycoA-) MSC (STRO-1+) percentage in the cell solution was greater than 70%. This 
population is highly osteogenic [15, 17] and in combination with the production of alkaline phosphatase and 
mineralization further illustrates the expected efficacy of this cell suspension. By including supportive cell 
populations in the cell solution, the efficacy should be further enhanced, without fear of immune reactions. 
We have shown that BM allograft material can be isolated in a specific media and cryopreserved without 
antibody-based isolation, producing an effective and safe bone healing product. The resulting material contains 
greater than 50% CD45-CD105+ MSCs and greater than 70% GlycoA-STRO1+ MSCs. The percentage of 
MSCs is more than sufficient to nullify unfavorable immune responses from both donor and recipient. Our data 
shows excellent reduction of immune cells and erythrocytes upon isolation with continued marked reduction 
following cryopreservation. These results are further enhanced by the concurrent increase in mesenchymal stem 
cell concentration. We have shown that the presence of supportive cell populations in combination with high 
concentration of MSCs yield a well-rounded transplantable allograft that is producible without significant cell 
manipulation and without exposure of cells to adherence cleaving enzymes commonly used for retrieval of 
MSCs. There are no toxic, damaging cryopreservants or exposure to cyropreservants with media’s that contain 
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potentially unsafe serums. Taken together, this data illustrates the safety of bone marrow cells which are isolated 
and preserved in this manner. 
This study is constrained to the testing of a singular poly-l-lysine based cryopreservant. Hence, the results are 
limited to the properties of that preservant. We recommend expansion of the concept and extended testing to 
include other non-DMSO cryopreservants. Although these data would be best presented as a comparison to 
DMSO-based industry standards, this formulation is not safe for direct application. Therefore, in vitro 
comparative studies will need to suffice as preliminary data. Animal studies utilizing DMSO-based 
crypreservants without washing are not recommended due to toxic effects. 
Bone allograft is commonly used to enhance healing of non-union fractures and encourage fusion of bone 
following surgery. The cell solution as a component of a reconstituted cellular allograft described herein 
introduces options for clinical care for bone defects, surgical imperfections, or traumatic loss of skeletal 
material. Combination of this solution with bone microparticulate would strongly enhance the healing properties 
of both the cells and the microparticulate, working in synergy with the patient’s bone microenvironment. The 
application of MSCs to patients have already been shown to be safe in ratios of MSCs to other cells far below 
that of our solution. Since this cell solution remains viable, is expected to suppress immune responses and will 
osteogenically differentiate, it is an ideal candidate for testing with bone microparticulate transplanted to non-
union fracture or fusion scenarios. There is also the consideration that this cell solution will differentiate 
effectively into cartilage in the presence of appropriate environmental cues. There are many avenues to be 
investigated for discovery of the limits and applications of this cell solution, isolated and preserved in this 
manner. 
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